On this page of StockholderLetter.com we present the latest annual shareholder letter from VERACYTE, INC. — ticker symbol VCYT. Reading current and past VCYT letters to shareholders can bring important insights into the investment thesis.
2023 Annual Report
Our vision is to transform cancer care for patients all over the world mic assays + clinic eno al g d da oa ta r a d t d a e t m s B i ni n ssi a g AI Rob us t& Differ en tia Veracyte Diagnostics Platform e gin en ach n pro ap vidence ge ne nt e e i ra c ti o ffi e t e x e k p r ans a m ion d te The Veracyte Diagnostic platform is a unique approach to developing and launching diagnostic tests that delivers: More data More insights More evidence More utility This unique approach builds a ywheel for market expansion and value creation that can be applied down the cancer continuum and to new cancer challenges or indications. North America South San Francisco, CA 6000 Shoreline Court Suite 300 S. San Francisco, CA 94080 International San Diego, CA 6925 Lusk Boulevard Suite 200 San Diego, CA 92121 Austin, TX 12357-A Riata Trace Parkway Building 5, Suite 100 Austin, TX 78727 Marseille, France 163 Avenue de Luminy 13009 Marseille FRANCE Haifa, Israel Nahum Het 7 Haifa, Israel 3508506 ISRAEL
 • shareholder letter icon 4/25/2024 Letter Continued (Full PDF)
 • stockholder letter icon 4/27/2023 VCYT Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon VCYT Benford's Law Stock Score = 87


VCYT Shareholder/Stockholder Letter Transcript:

2023 Annual Report

Our vision is to transform
cancer care for patients
all over the world
mic assays + clinic
eno
al
g
d
da
oa
ta
r
a
d
t
d
a
e
t
m
s
B
i ni n
ssi
a
g
AI
Rob
us
t&
Differ
en
tia
Veracyte
Diagnostics
Platform
e
gin
en
ach
n
pro
ap
vidence ge
ne
nt e
e
i
ra
c
ti o
ffi
e
t
e
x
e
k
p
r
ans
a
m
ion
d
te
The Veracyte Diagnostic platform is a
unique approach to developing and
launching diagnostic tests that delivers:
    More data
    More insights
    More evidence
    More utility
This unique approach builds a    ywheel
for market expansion and value creation
that can be applied down the cancer
continuum and to new cancer
challenges or indications.
North America
South San Francisco, CA
6000 Shoreline Court
Suite 300
S. San Francisco, CA 94080
International
San Diego, CA
6925 Lusk Boulevard
Suite 200
San Diego, CA 92121
Austin, TX
12357-A Riata Trace
Parkway
Building 5, Suite 100
Austin, TX 78727
Marseille, France
163 Avenue de Luminy
13009 Marseille FRANCE
Haifa, Israel
Nahum Het 7
Haifa, Israel 3508506 ISRAEL



shareholder letter icon 4/25/2024 Letter Continued (Full PDF)
 

VCYT Stockholder/Shareholder Letter (VERACYTE, INC.) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.